Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 23,500 shares, a decrease of 20.6% from the October 15th total of 29,600 shares. Based on an average trading volume of 31,700 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.4% of the shares of the stock are sold short.
Institutional Trading of Creative Medical Technology
An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned 1.21% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is currently owned by hedge funds and other institutional investors.
Creative Medical Technology Price Performance
Shares of NASDAQ CELZ traded up $0.04 during midday trading on Friday, hitting $2.70. The company’s stock had a trading volume of 20,364 shares, compared to its average volume of 71,907. The business’s fifty day simple moving average is $3.47 and its two-hundred day simple moving average is $3.70. The firm has a market capitalization of $4.73 million, a price-to-earnings ratio of -0.71 and a beta of 2.01. Creative Medical Technology has a 1 year low of $2.52 and a 1 year high of $10.28.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.
Read More
- Five stocks we like better than Creative Medical Technology
- There Are Different Types of Stock To Invest In
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top-Performing Non-Leveraged ETFs This Year
- High Flyers: 3 Natural Gas Stocks for March 2022
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
